Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Atea Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
48.6
351
Research and development
6.68
10.2
38
167
81.9
114
144
148
General and administrative
2.8
4.44
21.6
45.8
48.7
49.9
48.8
32.9
Operating expenses
9.48
14.6
59.7
213
131
164
193
181
Operating income
-9.48
-14.6
-11
138
-131
-164
-193
-181
Pre-tax income
-14
-10.9
139
-119
-135
-167
-165
Income tax
17.4
-3.59
1.02
0.93
-6.16
Net income
-9.06
-14
-10.9
121
-116
-136
-168
-158
EBITDA
-9.46
-14.6
-11
138
-130
-164
-193
-180
EPS, basic
-0.90
-1.39
-0.51
1.46
-1.39
-1.63
-2.00
-1.94
EPS, diluted
-0.90
-1.39
-0.51
1.37
-1.39
-1.63
-2.00
-1.94
Shares, basic (weighted)
10
10.1
21.6
82.8
83.2
83.4
84.3
81.5
Shares, diluted (weighted)
10
10.1
21.6
88.2
83.2
83.4
84.3
81.5
Balance sheet
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
34.5
21.7
850
764
188
144
64.7
95.7
Short-term investments
458
434
390
206
Other current assets
0.25
7.55
8.03
14.2
12.3
7.63
9.16
Total current assets
21.9
863
772
661
590
462
311
Property, plant and equipment
0.04
0.05
0.02
1.71
1.29
0.87
0.46
Lease right-of-use assets
0.16
2.39
1.83
1.24
0.63
Long-term investments
0
0
0
Other non-current assets
0.12
0.11
0.47
1.49
1.4
0.2
3.14
Total assets
22.1
864
773
667
595
465
315
Accounts payable
0.55
0.06
4.53
2.55
4.25
4.46
12.9
Accrued liabilities
2.74
4.21
6.46
5.7
5.9
6.44
Deferred revenue
301
Total current liabilities
2.44
316
56.9
18.5
32.4
18.6
39.8
Lease liabilities
2.4
1.64
0.84
0
Other non-current liabilities
0.1
0.04
5.93
Total liabilities
2.53
316
62.8
26.1
39.8
25.8
39.8
Paid-in capital
4.63
613
654
701
751
803
798
Retained earnings
-54.2
-65.2
56
-59.9
-196
-364
-523
Other comprehensive income
-0.68
0.21
0.23
0.17
Shareholders' equity
-36.2
-49.6
548
710
641
555
439
275
Total equity
-36.2
-49.6
548
710
641
555
439
275
Total liabilities and equity
22.1
864
773
667
595
465
315
Shares outstanding
10.1
82.4
83.1
83.3
83.4
84.5
78.1
Cash flow statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-9.06
-14
-10.9
121
-116
-136
-168
-158
Depreciation and amortization
0.02
0.02
0.02
0.03
0.26
0.42
0.42
0.42
Stock-based compensation
0.41
0.62
7.46
39.6
46.7
49.4
51.8
20.7
Deferred income tax
0
0
0
0
-6.36
Change in receivables
-5.82
Change in payables
-0.09
0.16
-0.49
10.3
-1.98
1.7
0.21
8.49
Cash from operations
-7.91
-12.8
297
-87
-121
-85.4
-135
-132
Capital expenditures
-0.01
-0
-0.03
-0
-1.94
Purchases of investments
-545
-562
-461
-282
Sales and maturities of investments
91.9
603
517
471
Cash from investing
-0.01
-0
-0.03
-0
-455
40.3
56.1
189
Stock issued
0.12
0.03
1.47
0.23
0
0.06
Share buybacks
0
-25.5
Cash from financing
27.5
532
1.47
0.37
0.26
0.27
-25.7
Net change in cash
19.6
-12.8
828
-85.5
-576
-44.8
-79.1
31
Free cash flow
-7.92
-12.8
297
-87
-123
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.17 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-81.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-71.2%
Net income / average total assets.
Return on invested capital (ROIC)
-113.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-37.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-24.5%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-12.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-32.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-22.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-18.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
-3.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-0.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
30.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
8.13x
Current assets / current liabilities.
Quick ratio
7.80x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.80x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.90
Cash from operations / diluted weighted shares.
Book value per share
$2.55
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
2.03x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.03x
Market cap / tangible book value, when positive.
Earnings yield
-39.9%
Net income / market cap (the inverse of P/E).
Was Atea Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $158.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.